Lee S. Schwartzberg, MD
Results of a retrospective analysis demonstrated statistical significance in the incidence of febrile neutropenia between patients with nonmyeloid cancer who received a filgrastim (Neupogen) biosimilar (Zarxio; biosimilar filgrastim-sndz) versus the filgrastim biologic (filgrastim-ref) during their first chemotherapy cycle, explained lead author Lee Schwartzberg, MD.
Included in the study were those who were enrolled in commercial or Medicare Advantage insurance plans from March 2015 through June 2016 and received either filgrastim-sndz or filgrastim-ref. After adjusting for differences in baseline patient characteristics using the inverse probability of treatment-weighting method, there were 162 patients in the filgrastim-sndz cohort and 3297 in the filgrastim-ref cohort.
... to read the full story